Abstract:PURPOSE: This study aimed to develop a population pharmacokinetic (PPK) model for meropenem to optimize dosing regimens for critically ill patients with pulmonary infection.PATIENTS AND METHODS: This prospective PPK study of meropenem was conducted on a pooled dataset of 236 blood samples obtained from 48 patients with pulmonary infection in the intensive care unit. Meropenem plasma concentrations were measured by a validated high-performance liquid chromatography-tandem mass spectrometry method, and the data were analyzed using NONMEM. The effect of covariates on meropenem pharmacokinetics was investigated. The probability of target attainment (PTA) to achieve the target of 100% fT>MIC at the proposed dosage regimens were investigated by Monte Carlo simulations.RESULTS: A two-compartment model adequately described the data with estimated glomerular filtration rate (eGFR) as a covariate significantly associated with the clearance (CL) from the central compartment. The typical value of CL was 7.48 L/h, with an eGFR adjustment factor of 0.0103 mL•1.73 m2/min, and the typical values of volume of the central compartment (V1), peripheral compartmental clearance (Q), and volume of the peripheral compartment (V2) were 15.9 L, 15.8 L/h, and 14.8 L, respectively. The goodness-of-fit plots, normalized prediction distribution error, and visual predictive checks showed good fitting and predictability of the final PPK model. When eGFR was >90 mL/min/1.73 m2, and there was a short duration of infusion (<60min), it was difficult for the probability target attainment (PTA) to reach >90% for MIC ≥ 2. Continuous infusion and frequent administration were necessary to achieve the target of 100% fT>MIC for critically ill patients with pulmonary infection.CONCLUSION: To achieve the optimal PTA, meropenem must be administered by frequent administration or continuously by an intravenous infusion. Our findings provide important information to optimize the meropenem regime in critically ill patients with pulmonary infection depending on eGFR values.

Antibacterial Pharmacokinetics/pharmacodynamics and Optimizing Treatment of Nosocomial Pneumonia

Progress on pharmacokinetics/pharmacodynamics of antimicrobial agents

Optimizing the anti-infection therapy by the PK/PD theory

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant <i>Klebsiella pneumoniae</i>

Application of PK/PD Parameters in Selection of Antibiotic Regimes for Patients with Multi-Drug Resistant Bacterial Infection

[Antimicrobial Dosing Individualization Based on Pharmacokinetic/Pharmacodynamic Evaluation, Considering Factors of "Patient", "Site of infection" and "Microorganism"]

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models

Optimization of Polymyxin B Regimens for the Treatment of Carbapenem-Resistant Organism Nosocomial Pneumonia: a Real-World Prospective Study.

Overview the PK/PD research methods of anti-anaerobic drugs

Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies

Improving pharmacokinetic/pharmacodynamic outcomes of antimicrobial therapy for pneumonia in the ICU

Use of Pharmacodynamic Principles to Optimise Dosage Regimens for Antibacterial Agents in the Elderly

Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection

Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction

Correction of misunderstanding antimicrobial treatment to improve the rational use of antibi-otics

Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach

Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves

Advances in PK/PD studies of antifungals